NASDAQ:SNDX

Syndax Pharmaceuticals - SNDX Stock Forecast, Price & News

$21.12

+0.46 (+2.23%)

(As of 03/31/2023 12:00 AM ET)

Add

Compare

Today's Range: $20.66
▼
$21.43
50-Day Range: $20.66
▼
$28.98
52-Week Range: $13.27
▼
$29.86

Volume: 2.02 million shs
Average Volume: 931,768 shs
Market Capitalization: $1.45 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $33.57

Institutional Ownership

Syndax Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 59.0% Upside
$33.57 Price Target
Short Interest: Bearish
9.92% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.12
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$4.06 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.04) to ($3.00) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

197th out of 996 stocks

Pharmaceutical Preparations Industry

81st out of 484 stocks

4.5

Analyst's Opinion

Consensus Rating
Syndax Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $33.57, Syndax Pharmaceuticals has a forecasted upside of 59.0% from its current price of $21.12.
Amount of Analyst Coverage
Syndax Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
9.92% of the outstanding shares of Syndax Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 8.9.
Change versus previous month
Short interest in Syndax Pharmaceuticals has recently increased by 13.36%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Syndax Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Syndax Pharmaceuticals does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Syndax Pharmaceuticals has received a 66.26% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Syndax Pharmaceuticals is -1.12.

1.3

News and Social Media Coverage

News Sentiment
Syndax Pharmaceuticals has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Syndax Pharmaceuticals this week, compared to 2 articles on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Syndax Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,061,340.00 in company stock.
Percentage Held by Insiders
Only 6.30% of the stock of Syndax Pharmaceuticals is held by insiders.
Percentage Held by Institutions
99.11% of the stock of Syndax Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($3.04) to ($3.00) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Syndax Pharmaceuticals is -8.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Syndax Pharmaceuticals is -8.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Syndax Pharmaceuticals has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Syndax Pharmaceuticals (NASDAQ:SNDX) Stock

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Stock News Headlines

March 30, 2023 | finance.yahoo.com

Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development

March 24, 2023 | americanbankingnews.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 4%

April 2, 2023 | Legacy Research (Affiliate) (Ad)

Stocks are for suckers – try this instead

This has nothing to do with dividends, day trading... taking out a loan... or anything like that. What you need is about 3 seconds to execute this simple financial maneuver...

March 22, 2023 | americanbankingnews.com

Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) PT at $33.57

March 15, 2023 | finance.yahoo.com

Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know

March 6, 2023 | finance.yahoo.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

March 6, 2023 | finance.yahoo.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2022 Earnings Call Transcript

March 3, 2023 | markets.businessinsider.com

Robert W. Baird Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)

April 2, 2023 | Legacy Research (Affiliate) (Ad)

Bear market expert makes new prediction

Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.

March 1, 2023 | msn.com

Expert Ratings for Syndax Pharmaceuticals

March 1, 2023 | finance.yahoo.com

Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

February 27, 2023 | msn.com

Syndax Pharmaceuticals's Earnings: A Preview

February 21, 2023 | finance.yahoo.com

Syndax Pharmaceuticals (SNDX) Stock Moves -1.99%: What You Should Know

February 21, 2023 | finance.yahoo.com

Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023

February 14, 2023 | finance.yahoo.com

Syndax Announces Participation at Upcoming Investor Conferences

February 13, 2023 | finance.yahoo.com

Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know

February 1, 2023 | finance.yahoo.com

Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know

January 23, 2023 | finance.yahoo.com

Beat the Market Like Zacks: Boeing, Starbucks, Syndax Pharma in Focus

January 20, 2023 | finance.yahoo.com

Syndax (SNDX) Is a Great Choice for 'Trend' Investors, Here's Why

January 19, 2023 | finance.yahoo.com

Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal

January 18, 2023 | finance.yahoo.com

Are You Looking for a Top Momentum Pick? Why Syndax Pharmaceuticals (SNDX) is a Great Choice

January 17, 2023 | finance.yahoo.com

Syndax Pharmaceuticals (SNDX) Gains As Market Dips: What You Should Know

January 17, 2023 | finance.yahoo.com

Incyte (INCY) Up 7% in a Year: Will the Momentum Continue?

January 14, 2023 | seekingalpha.com

Syndax Pharmaceuticals (SNDX) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow

January 11, 2023 | finance.yahoo.com

Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know

January 10, 2023 | finance.yahoo.com

bluebird (BLUE) Updates on Progress With Zynteglo, 2023 Outlook

January 6, 2023 | markets.businessinsider.com

J.P. Morgan Bullish on These 2 Stocks for Over 60% Upside — This Is What Makes Them Attractive

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Company Calendar

Last Earnings: 2/28/2023
Today: 4/01/2023
Next Earnings (Estimated): 5/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNDX
CUSIP: N/A
CIK: 1395937
Web: www.syndax.com
Phone: (781) 419-1400
Fax: 781-419-1420
Employees: 59
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $33.57
High Stock Price Forecast: $37.00
Low Stock Price Forecast: $31.00
Forecasted Upside/Downside: +59.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.45)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-149,340,000.00
Net Margins: N/A
Pretax Margin: -11.02%
Return on Equity: -38.74%
Return on Assets: -35.44%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.85
Quick Ratio: 16.85

Sales & Book Value

Annual Sales: $139.71 million
Price / Sales: 10.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.76 per share
Price / Book: 2.72

Miscellaneous

Outstanding Shares: 68,440,000
Free Float: 64,131,000
Market Cap: $1.45 billion
Optionable: Optionable
Beta: 1.04

Key Executives

Michael A. Metzger
Chief Executive Officer & Director

Briggs W. Morrison
President & Director

Keith Alan Goldan
Chief Financial Officer & Treasurer

Peter Ordentlich
Chief Scientific Officer

Catherine Madigan
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SNDX Stock - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SNDX shares.
View SNDX analyst ratings or view top-rated stocks.
What is Syndax Pharmaceuticals' stock price forecast for 2023?: 6 brokerages have issued twelve-month target prices for Syndax Pharmaceuticals' shares. Their SNDX share price forecasts range from $31.00 to $37.00. On average, they expect the company's stock price to reach $33.57 in the next year. This suggests a possible upside of 59.0% from the stock's current price.
View analysts price targets for SNDX or view top-rated stocks among Wall Street analysts.
How have SNDX shares performed in 2023?: Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of 2023. Since then, SNDX stock has decreased by 17.0% and is now trading at $21.12.
View the best growth stocks for 2023 here.
When is Syndax Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our SNDX earnings forecast.
How were Syndax Pharmaceuticals' earnings last quarter?: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its quarterly earnings results on Tuesday, February, 28th. The company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.02.
What ETFs hold Syndax Pharmaceuticals' stock?: ETFs with the largest weight of Syndax Pharmaceuticals (NASDAQ:SNDX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) and Invesco Nasdaq Biotechnology ETF (IBBQ).

What other stocks do shareholders of Syndax Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).
When did Syndax Pharmaceuticals IPO?: (SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.
What is Syndax Pharmaceuticals' stock symbol?: Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."
How do I buy shares of Syndax Pharmaceuticals?: Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Syndax Pharmaceuticals' stock price today?: One share of SNDX stock can currently be purchased for approximately $21.12.
How much money does Syndax Pharmaceuticals make?: Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $1.45 billion and generates $139.71 million in revenue each year. The company earns $-149,340,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.
How can I contact Syndax Pharmaceuticals?: Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420.

This page (NASDAQ:SNDX) was last updated on 4/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Syndax Pharmaceuticals - SNDX Stock Forecast, Price & News

Syndax Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Syndax Pharmaceuticals (NASDAQ:SNDX) Stock

SNDX Stock News Headlines

SNDX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SNDX Stock - Frequently Asked Questions

Overall MarketRank^™